Bilenker Joshua H. 4
4 · Sana Biotechnology, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Sana (SANA) Director Joshua H. Bilenker Receives Award
What Happened Joshua H. Bilenker, a director of Sana Biotechnology, Inc. (SANA), received a grant of derivative securities covering 90,000 shares on June 4, 2026. The Form 4 reports the transaction as an award/acquisition (code A) with a reported price of $0.00 (i.e., a grant of an option/award rather than a market purchase). No cash value or exercise price is provided in the information summarized here.
Key Details
- Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (timely filing).
- Transaction type: Grant of derivative securities (code A) — 90,000 shares; reported price $0.00.
- Vesting/exercise: Footnote F1 — the option vests and becomes exercisable 100% on the earlier of (i) June 4, 2027 or (ii) immediately prior to the 2027 annual meeting of stockholders, provided continuous service through that date.
- Shares owned after transaction: Not specified in the provided report.
- Exhibit noted: Ex. 24 — Power of Attorney.
Context This is a derivative award (an option-type grant) that does not represent immediate share ownership or a market purchase/sale. The award vests in full on a specified future date contingent on continued service; there is no indication the shares were exercised or sold. Such grants are common for board compensation and do not by themselves signal an immediate trading view.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-04+90,000→ 90,000 totalExercise: $2.96Exp: 2036-06-03→ Common Stock (90,000 underlying)
Footnotes (1)
- [F1]The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.